Literature DB >> 25999051

Analysis of RAS mutation and PAX8/PPARγ rearrangements in follicular-derived thyroid neoplasms in a Korean population: frequency and ultrasound findings.

S H Jeong1, H S Hong, J J Kwak, E H Lee.   

Abstract

OBJECTIVE: To investigate the frequency and ultrasonography (US) findings of RAS mutations and PAX8/PPARγ rearrangements between follicular thyroid adenomas (FTAs) and follicular thyroid carcinomas (FTCs) in a Korean population.
METHODS: RAS mutations and PAX8/PPARγ rearrangements in 56 FTAs and 35 FTCs were analyzed. We also analyzed the US findings of FTCs and FTAs.
RESULTS: 16 nodules of 35 FTCs (45.7 %) and 19 nodules of 56 FTAs (33.9 %) harbored RAS mutations. Three FTCs and three FTAs showed two point mutations simultaneously. K-RAS codon 12-13 (n = 6, 31.6 %), N-RAS codon 61 (n = 5, 26.3 %), H-RAS codon 61 (n = 4, 21.1 %), K-RAS codon 61 (n = 3, 15.8 %), and N-RAS codon 12-13 (n = 1, 5.3 %) were found in FTCs, and N-RAS codon 61 (n = 10, 45 %), K-RAS codon 12-13 (n = 5, 22.7 %), H-RAS codon 61 (n = 5, 22.7 %), K-RAS codon 61 (n = 1, 4.5 %), and N-RAS codon 12-13 (n = 1, 4.5 %) were observed in FTAs. 4 of 56 (7.1 %) FTAs and 1 of 35 (2.9 %) FTCs represented PAX8/PPARγ rearrangements, respectively (P = 0.645). The absence of a hypoechoic rim (P = 0.021) and presence of calcifications (P = 0.049) were significantly associated with FTCs compared with FTAs.
CONCLUSIONS: RAS mutation frequency targeting the Korean population showed a 45.7 % in FTCs and 35.7 % in FTAs, and PAX8/PPARγ rearrangements were more frequently showed in FTAs. K-RAS codon 12-13 was the most common RAS mutation in FTCs, whereas N-RAS codon 61 was more frequent in FTAs. The presence of calcifications and absence of a hypoechoic rim showed more frequently in FTCs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25999051     DOI: 10.1007/s40618-015-0311-x

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  Prevalence of Ras mutations in thyroid neoplasia.

Authors:  C T Esapa; S J Johnson; P Kendall-Taylor; T W Lennard; P E Harris
Journal:  Clin Endocrinol (Oxf)       Date:  1999-04       Impact factor: 3.478

2.  The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.

Authors:  Michiko Fukahori; Akira Yoshida; Hiroyuki Hayashi; Mitsuyo Yoshihara; Shoichi Matsukuma; Yuji Sakuma; Shiro Koizume; Naoyuki Okamoto; Tetsuo Kondo; Munetake Masuda; Yohei Miyagi
Journal:  Thyroid       Date:  2012-05-31       Impact factor: 6.568

3.  Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

Authors:  Ana Rita Marques; Carla Espadinha; Ana L Catarino; Sónia Moniz; Teresa Pereira; Luís G Sobrinho; Valeriano Leite
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

4.  Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.

Authors:  Rue-Tsuan Liu; Chia-Yi Hou; Huey-Ling You; Chao-Cheng Huang; Fong-Fu Chou; Pei-Wen Wang; Jiin-Tsuey Cheng
Journal:  Thyroid       Date:  2004-08       Impact factor: 6.568

5.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

6.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

Authors:  V Vasko; M Ferrand; J Di Cristofaro; P Carayon; J F Henry; C de Micco
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

7.  Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.

Authors:  Ana Banito; António E Pinto; Carla Espadinha; Ana Rita Marques; Valeriano Leite
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-25       Impact factor: 3.478

8.  Follicular thyroid carcinoma: histology and prognosis.

Authors:  Alessandra D'Avanzo; Patrick Treseler; Philip H G Ituarte; Mariwil Wong; Leanne Streja; Francis S Greenspan; Allan E Siperstein; Quan-Yang Duh; Orlo H Clark
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

9.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

10.  ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Authors:  K Yoshimoto; H Iwahana; A Fukuda; T Sano; K Katsuragi; M Kinoshita; S Saito; M Itakura
Journal:  Jpn J Cancer Res       Date:  1992-10
View more
  7 in total

1.  Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.

Authors:  Jie Ming; Zeming Liu; Wen Zeng; Yusufu Maimaiti; Yawen Guo; Xiu Nie; Chen Chen; Xiangwang Zhao; Lan Shi; Chunping Liu; Tao Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 2.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

Review 3.  Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.

Authors:  Young Shin Song; Jung Ah Lim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2015-09

4.  Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population.

Authors:  Sun Hye Jeong; Hyun Sook Hong; Eun Hye Lee; Jeong Ja Kwak; Ji Ye Lee
Journal:  Endocrinol Diabetes Metab       Date:  2018-09-03

5.  Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.

Authors:  Seung-Hyun Jung; Min Sung Kim; Chan Kwon Jung; Hyun-Chun Park; So Youn Kim; Jieying Liu; Ja-Seong Bae; Sung Hak Lee; Tae-Min Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2016-10-25

6.  Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer.

Authors:  Zunfu Ke; Yihao Liu; Yunjian Zhang; Jie Li; Ming Kuang; Sui Peng; Jinyu Liang; Shuang Yu; Lei Su; Lili Chen; Cong Sun; Bin Li; Jessica Cao; Weiming Lv; Haipeng Xiao
Journal:  Oncol Rep       Date:  2018-06-14       Impact factor: 3.906

7.  Whole-genome Sequencing of Follicular Thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.

Authors:  Johan O Paulsson; Nima Rafati; Sebastian DiLorenzo; Yi Chen; Felix Haglund; Jan Zedenius; C Christofer Juhlin
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.